Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care
Standard
Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. / da Silva, Neuza Maria Bernardino; Augustin, Matthias; Langenbruch, Anna Katharina; Mrowietz, Ulrich; Reich, Kristian; Thaçi, Diamant; Boehncke, Wolf-Henning; Kirsten, Natalia; Danckworth, A; Sommer, Rachel.
in: EUR J DERMATOL, Jahrgang 30, Nr. 3, 11.08.2020, S. 267-278.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care
AU - da Silva, Neuza Maria Bernardino
AU - Augustin, Matthias
AU - Langenbruch, Anna Katharina
AU - Mrowietz, Ulrich
AU - Reich, Kristian
AU - Thaçi, Diamant
AU - Boehncke, Wolf-Henning
AU - Kirsten, Natalia
AU - Danckworth, A
AU - Sommer, Rachel
PY - 2020/8/11
Y1 - 2020/8/11
N2 - Background: Psoriasis may cause considerable disease burden. The involvement of sexually-sensitive/visible body areas has been associated with decreased quality of life (QoL), more depressive symptoms and stigmatisation experiences. Objectives: To characterise the topical distribution of psoriasis in sexually-sensitive and visible areas, to examine its impact on QoL and to determine which specific patient needs should be addressed in routine care. Materials and Methods: Patients with psoriasis vulgaris were recruited within a cross-sectional nationwide survey, involving 157 randomly assigned German dermatology practices/clinics. The main outcome measures were the EuroQoL visual analogue scale (EQ VAS), the Dermatology Life Quality Index (DLQI), the Patient Needs Questionnaire (PNQ) and a grid scheme for topical distribution of psoriasis. Results: The sample included 2,009 patients (43.7% female; 21.8% ≥ 65 years; 64.2% with lesions in sexually-sensitive areas and 86.2% with lesions in visible areas). Patients with concomitant involvement of sexually-sensitive and visible areas presented increased DLQI impairments relative to patients with no involvement of sexually-sensitive or visible areas (F(3, 1723) = 4.091, p = 0.007). Significant differences were also found for patient needs dimensions (PNQ) depending on the body areas affected (F(15, 4602) = 2.936, p<0.001). Significant effects of gender and age group were also observed. Increased disease severity, lesions in both sexually-sensitive/visible or only visible areas, and increased QoL impairment were associated with specific patient needs. Conclusion: These results highlight the need for proactive evaluation of difficult-to-communicate impairments and the requirements for patient-centred routine care.
AB - Background: Psoriasis may cause considerable disease burden. The involvement of sexually-sensitive/visible body areas has been associated with decreased quality of life (QoL), more depressive symptoms and stigmatisation experiences. Objectives: To characterise the topical distribution of psoriasis in sexually-sensitive and visible areas, to examine its impact on QoL and to determine which specific patient needs should be addressed in routine care. Materials and Methods: Patients with psoriasis vulgaris were recruited within a cross-sectional nationwide survey, involving 157 randomly assigned German dermatology practices/clinics. The main outcome measures were the EuroQoL visual analogue scale (EQ VAS), the Dermatology Life Quality Index (DLQI), the Patient Needs Questionnaire (PNQ) and a grid scheme for topical distribution of psoriasis. Results: The sample included 2,009 patients (43.7% female; 21.8% ≥ 65 years; 64.2% with lesions in sexually-sensitive areas and 86.2% with lesions in visible areas). Patients with concomitant involvement of sexually-sensitive and visible areas presented increased DLQI impairments relative to patients with no involvement of sexually-sensitive or visible areas (F(3, 1723) = 4.091, p = 0.007). Significant differences were also found for patient needs dimensions (PNQ) depending on the body areas affected (F(15, 4602) = 2.936, p<0.001). Significant effects of gender and age group were also observed. Increased disease severity, lesions in both sexually-sensitive/visible or only visible areas, and increased QoL impairment were associated with specific patient needs. Conclusion: These results highlight the need for proactive evaluation of difficult-to-communicate impairments and the requirements for patient-centred routine care.
U2 - 10.1684/ejd.2020.3768
DO - 10.1684/ejd.2020.3768
M3 - SCORING: Journal article
VL - 30
SP - 267
EP - 278
JO - EUR J DERMATOL
JF - EUR J DERMATOL
SN - 1167-1122
IS - 3
ER -
